Shots: The US FDA has issued a EUA for Actemra/RoActemra to treat COVID-19 in hospitalized adults & pediatric patients aged >2 yrs. who are receiving systemic corticosteroids & require supplemental […]readmore
Shots: The P-III EMPACTA study involves assessing of Actemra + SOC vs PBO + SOC in 389 patients aged > 18yrs. with confirmed SARS-CoV-2 (COVID-19) infection with SpO2 <94% while […]readmore
The emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop […]readmore
Shots: The P-III REMDACTA study involves assessing of Actemra + remdesivir vs PBO + remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving SOC with 1EPs & 2EPs as clinical […]readmore
Shots: Chugai has filed a clinical trial notification with the PMDA to conduct a P-III clinical study of Actemra (tocilizumab, IV, 80mg/200mg/400mg) to treat hospitalized patients with severe COVID19 pneumonia […]readmore
Shots: The US FDA has approved the P-III clinical study assessing Actemra (tocilizumab, IV) + SOC vs PBO + SOC in adult patients hospitalized with severe COVID-19 pneumonia with its […]readmore
Shots: China’s National Health Commission reports in its treatment guidelines that Roche’s Actemra can be used to treat coronavirus patients with serious lung damage and high IL-6 levels Researchers are […]readmore
Copyright © 2020 Digiqole. All Right Reserved.